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Review
Treatment of intracerebral
hemorrhage: From specific
interventions to bundles of care
Adrian R Parry-Jones1,2 , Tom J Moullaali3,4 and Wendy C Ziai5
Abstract
Intracerebral hemorrhage (ICH) represents a major, global, unmet health need with few treatments. A significant
minority of ICH patients present taking an anticoagulant; both vitamin-K antagonists and increasingly direct oral anti-
coagulants. Anticoagulants are associated with an increased risk of hematoma expansion, and rapid reversal reduces this
risk and may improve outcome. Vitamin-K antagonists are reversed with prothrombin complex concentrate, dabigatran
with idarucizumab, and anti-Xa agents with PCC or andexanet alfa, where available. Blood pressure lowering may reduce
hematoma growth and improve clinical outcomes and careful (avoiding reductions60 mm Hg within 1 h), targeted (as
low as 120–130 mm Hg), and sustained (minimizing variability) treatment during the first 24 h may be optimal for
achieving better functional outcomes in mild-to-moderate severity acute ICH. Surgery for ICH may include hematoma
evacuation and external ventricular drainage to treat hydrocephalus. No large, well-conducted phase III trial of surgery in
ICH has so far shown overall benefit, but meta-analyses report an increased likelihood of good functional outcome and
lower risk of death with surgery, compared to medical treatment only. Expert supportive care on a stroke unit or critical
care unit improves outcomes. Early prognostication is difficult, and early do-not-resuscitate orders or withdrawal of
active care should be used judiciously in the first 24–48 h of care. Implementation of acute ICH care can be challenging,
and using a care bundle approach, with regular monitoring of data and improvement of care processes can ensure
consistent and optimal care for all patients.
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Introduction
Intracerebral hemorrhage (ICH) represents a major
cause of morbidity and mortality on a global scale.
Of the 12 million incident strokes worldwide in 2017,
over a quarter were due to ICH and because of the
relatively high case fatality of ICH, hemorrhagic
stroke accounts for just over half of all global stroke
deaths.1,2 Considerable regional differences exist in inci-
dence, prevalence, deaths, and disability, with much of
the global burden of ICH residing in Asia, Africa, and
Eastern Europe.1
Hypertension is the key modifiable risk factor for
ICH, accounting for over half of the population attrib-
utable risk.3 Whilst improvements in the management
of this key risk factor would be expected to have
reduced ICH incidence in high income countries, ICH
incidence has remained largely unchanged over the last
30 years,1 perhaps due to a rising incidence of cerebral
amyloid angiopathy-related ICH associated with
antithrombotic use in the elderly.4
Despite the considerable and ongoing burden of
ICH, there remain few effective therapies when com-
pared to ischemic stroke. However, evidence-based
treatments when combined may have a considerable
impact on outcome, and consistent and effective imple-
mentation can be supported by a ‘‘care bundle’’
approach, such as the recently described ‘‘ABC’’ care
bundle for ICH.5 Here, we review the key interventions
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recommended in the first 72 h of ICH care and consider
how these interventions can be effectively implemented.
To aid clarity for the practicing clinician, we present
these interventions in the order in which we believe
they should be considered and delivered in the majority
of ICH patients, focusing initially on reversal of antith-
rombotic drugs, followed by acute management of
blood pressure (BP), then consideration for neurosur-
gical intervention, and finally deciding the appropriate
level of ongoing supportive care for each patient.
Antithrombotic medications
Around a third of ICH patients are taking anticoagu-
lants or antiplatelet drugs at ICH onset and manage-
ment of this issue has been further complicated by the
introduction of the direct oral anticoagulants (DOACs)
in addition to vitamin-K antagonists (VKAs). VKA-
ICH patients tend to be older and have a larger hema-
toma at baseline, a three-fold higher odds of hematoma
expansion and a higher mortality when compared to
those not taking anticoagulants.6 DOAC-ICH appears
to be associated with lower baseline hematoma volume
and less severe stroke syndromes, but not a lower case-
fatality when compared to VKA-ICH.7 Restoration of
vitamin-K-dependent clotting factors in VKA-ICH and
normalization of the INR can be achieved rapidly by
treatment with four-factor prothrombin complex con-
centrate (PCC), which has shown to be superior to fresh
frozen plasma.8 Rapidly achieving normalization of the
INR appears to be associated with a lower risk of
hematoma expansion,9 so the mantra of ‘‘time is
brain’’ applies to ICH as well. Clinicians should thus
work to minimize delays in care processes, and the use
of point-of-care INR testing, agreed protocols, and
rapid access to PCC has all been shown to help.10
Ambulance pre-alerting of all cases of suspected
stroke on anticoagulants can reduce door-to-scan time
significantly.11 Dabigatran can be reversed with idaru-
cizumab, a monoclonal antibody fragment that leads to
a rapid and sustained reversal of the anticoagulant
effect.12 Until recently, the anti-Xa agents (apixaban,
edoxaban, rivaroxaban, and betrixaban) have not had
a licensed and specific reversal agent, and PCC has been
recommended in guidelines.13,14 Healthy volunteer stu-
dies have shown that PCC at a dose of 50 IU/kg can
correct endogenous thrombin potential and may reduce
bleeding time.15 Observational studies without com-
parator arms have reported experience in giving PCC
at lower doses in ICH and report effective hemostasis in
around two-thirds and thromboembolic complications
in 2.4–7.6% of patients.16,17 Andexanet alfa is a mod-
ified recombinant inactive form of human factor Xa,
which binds specifically to anti-Xa agents and is
licensed for use in life-threatening and uncontrolled
bleeding in patients treated with apixaban and rivarox-
aban.18 Seventy-one cases with relatively small ICH
volume were included in a single-arm clinical trial of
andexanet alfa and 23% had expansion >35% by 12 h
and 10.9% of patients with ICH had a thrombotic
event within 30 days of treatment.18,19 The lack of a
comparator arm makes interpretation difficult but this
will be addressed by the ongoing ANNEXa-I trial
(andexanet alfa vs. standard care in ICH).
Prior antiplatelet use is associated with a larger base-
line ICH volume, more hematoma growth, increased
mortality but not a worse long-term functional out-
come20 so may represent a therapeutic target. The
PATCH trial randomized 190 patients with ICH
taking antiplatelet drugs to platelet transfusion vs.
standard care and showed, somewhat surprisingly,
that platelet transfusion led to significantly higher
death and dependence at 90 days so should thus be
avoided for this indication.21 Although other treat-
ments such as desmopressin are under investigation,
aside from discontinuation of antiplatelets in the
acute phase, there are currently no treatments of benefit
in antiplatelet-associated ICH.
Although there is currently insufficient evidence to
recommend routine use in ICH patients with normal
clotting, recombinant activated factor VII (rFVIIa)
and tranexamic acid may warrant further investigation.
Tranexamic acid led to modest but significant reduc-
tions in early death, hematoma expansion and
appeared safe in the large, phase III TICH-2 trial, but
did not improve the modified Rankin Scale (mRS) at 90
days.22 Similarly, the FAST trial of rFVIIa showed a
reduction in hematoma expansion but no improvement
in 90-day mRS as well as an increase in thrombo-
embolic complications at the highest dose.23 Further
trials are either underway or planned, and targeting
subgroups with the highest risk of hematoma expansion
(e.g. very early after symptom onset) may lead to
improvements in long-term clinical outcomes.
Blood pressure management
High blood pressure (BP) occurs in 75% of patients
with acute ICH, where impaired cerebral autoregula-
tion and activation of the autonomic nervous system
contribute to the hypertensive response.24 Persistent
or episodic high BP may contribute to ongoing bleed-
ing, and observational studies support there being an
association with adverse outcomes, including growth of
the underlying hematoma, and subsequent death and
disability.25
Several randomized controlled trials have tested
various targeted BP-lowering strategies in acute ICH
patients.26–30 The first large trial to test intensive BP
lowering in acute ICH, INTERACT2, reported a
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modest benefit from treatment on 90-day functional
outcome and health-related quality of life,28 and inter-
national guidelines were updated to recommend BP
lowering in selected patients.13,31 However, the second
trial, ATACH-II, found no effect of treatment on 90-
day death and major disability and that renal adverse
events were more common in the treatment group.30
Meta-analyses of study-level data from these and
other small trials reported no benefit of treatment on
death and major disability, despite modest reductions
in hematoma growth.32,33 However, these analyses did
not account for the manner in which BP was lowered:
although INTERACT2 and ATACH-II had similar
designs (Table 1), BP was probably lowered more
aggressively in ATACH-II, raising questions about
the optimal approach to balance potential benefits
(reductions in hematoma growth, improved function)
and harms (cerebral, cardiac, or renal ischemia) from
intensive BP lowering.
In analyses of pooled patient-level data from
INTERACT2 and ATACH-II, linear associations
existed for mean and variability of systolic BP during
the first 24 h of treatment, whereby lower (as low as
120–130mm Hg) and stable levels of systolic BP were
safe and associated with favorable functional out-
come.34 However, in secondary analyses, inverted
U-shaped curves were apparent between categories of
magnitude of systolic BP reduction within the first hour
and death and neurological deterioration, suggesting
harms may exist where large reductions (60mm Hg)
occurred within the first hour of treatment. Therefore,
careful, targeted and sustained BP reductions may be
beneficial, but reverse causality cannot be excluded.
Furthermore, included patients had mild-to-moderate
severity ICH, so caution should be applied in patients
with large hematomas and severe neurological
impairment.
Regarding timing of the treatment, a recent post-hoc
analysis of ATACH-II showed that a subgroup of
patients who received ultra-early (time from symptom
onset to treatment <2 h) intensive BP lowering had less
hematoma growth and better functional outcomes.35
However, subgroup analyses of the RIGHT2 trial
that tested ultra-early (median time from symptom
onset to randomization 74min) use of topical nitrates
in acute stroke in the pre-hospital setting showed a non-
significant trend toward harm in ICH.36 These findings
raise questions about the potential for ultra-early vaso-
dilators to interrupt important hemostatic mechan-
isms37 and require further randomized evidence for
confirmation.
Table 1. Comparison of two large trials that tested intensive vs. guideline blood pressure lowering in acute intracerebral
hemorrhage.
INTERACT2 ATACH-II
Eligibility
Time window <6 h <4.5 h
Baseline SBP 150–220 mm Hg 180–240 mm Hg
Notable exclusions Poor prognosis (death expected within 24 h) Those with IVH where blood completely fills
one lateral ventricle; recent warfarin use
Intervention
Target Lower mean SBP to <140 mm Hg within 1 h
of randomization and maintain for seven
days
Lower minimum SBP to 120–139 mm Hg
within 2 h of randomization and maintain
for 24 h
Agent Physician discretion (locally agreed protocol) IV nicardipine; rescue agents allowed
Treatment cessation Stop IV treatment is SBP< 130 mm Hg Stop treatment if SBP< 110 mm Hg
Control group Target mean SBP< 180 mm Hg Target minimum SBP 140–179 mm Hg
Findings No effect of treatment of death or depend-
ency (mRS scores 3–6); modest benefit of
treatment on function (ordinal mRS scores)
and health-related quality of life
No effect of treatment on death or major
disability (mRS 4–6); preponderance of
renal adverse events in treatment group
SBP: systolic blood pressure; IV: intravenous; IVH: intraventricular hemorrhage; mRS: modified Rankin Scale, where 0 ¼ no disability and 6 ¼ death).
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There are no reliable data to support the choice of
BP-lowering agent in acute ICH. In INTERACT2,
alpha-adrenoreceptor blockers were the most fre-
quently used agent in the treatment group; however,
nearly half of all participants were treated with multiple
agents. Data from several randomized trials, where
alpha- and beta-adrenoreceptor blockers, angiotensin
receptor blockers, calcium channel blockers, magne-
sium, and nitrates were used are available, and the
results of a patient-level meta-analysis are awaited.38
Until robust data are available, locally agreed protocols
that take into account clinicians’ familiarity and pref-
erences are reasonable.
Neurosurgery
Surgical hematoma evacuation is hypothesized to cor-
rect parenchymal displacement, decrease intracranial
pressure (ICP), and mitigate neurotoxic and inflamma-
tory cascades, but evidence to date is inconclusive. The
STICH trial compared early craniotomy and hema-
toma evacuation with initial conservative management
in supratentorial ICH and showed no overall benefit in
mortality or favorable outcome at six months.39 STICH
II compared early surgery in a more selected population
of lobar hemorrhage without intraventricular hemor-
rhage (IVH) hypothesized to be more likely to benefit,
but surgery again showed no overall benefit.40 More
recently, there has been considerable interest in minim-
ally invasive surgery (MIS), and multiple techniques are
available, including image-guided (stereotactic) aspir-
ation of the hematoma with or without the use of
thrombolytic drugs, craniopuncture, mechanical clot
disruption, and endoscopic removal including with con-
tinuous focal ultrasound delivered directly into the
ICH. Refinement of MIS procedures is beginning to
challenge clinical equipoise regarding volume-reduction
therapy for ICH even for deep hemorrhage. MISTIE
III, the largest clinical trial of MIS to date, demon-
strated an improvement in mortality, but not functional
outcome at one year.41 A significant improvement in
functional outcome was suggested by a post-hoc ana-
lysis of MISTIE III patients with an ICH volume
15mL at the end of treatment (Figure 1),42 suggesting
that achieving adequate hematoma clearance may be
crucial in achieving improved outcomes.
Systematic reviews and meta-analyses of studies
evaluating surgical treatment in supratentorial ICH
have consistently concluded that the likelihood of sur-
vival and good functional outcome is significantly
higher in patients undergoing any surgical intervention
when compared to medical treatment only and even
higher in patients undergoing MIS compared to med-
ical treatment.43-45 These interventions may be more
effective in certain subgroups, specifically patients in
the moderate Glasgow Coma Scale (GCS) range
(5–12) with hemorrhage volume> 30mL and undergo-
ing surgery between 7 and 24 h.44 Whist early surgery
seems better, the potential for reducing secondary brain
injury from hematoma volume, expansion, intracranial
hypertension, and perihematomal edema must be
balanced against with the potential risk of early post-
surgical bleeding.
Decompressive hemicraniectomy without hematoma
evacuation can relieve elevated ICP and midline shift
caused by mass effect and associated PHE. Small case
series, case–control studies, and a meta-analysis report
improved survival with variable effects on functional
outcomes.46 The SWITCH trial compares decompres-
sive surgery to best medical treatment only in patients
with supratentorial ICH.
Though there have been no randomized clinical
trials of surgical evacuation in cerebellar ICH, it is rec-
ommended for patients with neurologic deterioration,
brainstem compression, and/or hydrocephalus.13 This
concept has been challenged by an individual patient
data meta-analysis of four observational ICH studies
with 578 patients with cerebellar ICH, reporting no
association between surgical evacuation and improved
Figure 1. Cubic spline (blue line) and linear spline (black
line) regression analyses showing the relationship of hema-
toma reduction (EOT ICH Volume) to the probability of
having a good outcome (green dots), mRS 0–3, (vs. a poor
outcome – red dots) at one year. Clot volume reduction
beyond the 15 mL goal increased the chances of improved
functional outcome by 10% for each additional milliliter
removed (p ¼ 0.002). Reprinted from Awad et al., Surgical
performance determines functional outcome benefit in the
Minimally Invasive Surgery Plus Recombinant Tissue
Plasminogen Activator for Intracerebral Hemorrhage
Evacuation (MISTIE) procedure, Neurosurgery 2019; 84:
1157–1168, by permission of the Congress of Neurological
Surgeons.
International Journal of Stroke, 0(0)
4 International Journal of Stroke 0(0)
functional outcome at three months on propensity
score-matched analysis.47 Survival, however, was
improved, with greater benefit for cerebellar hematoma
volume>15mL.
IVH occurs in 40–45% of ICH and is associated with
worse functional outcomes.48 External ventricular
drainage is recommended in cases of obstructive hydro-
cephalus, which complicates approximately half of
IVH.49 CLEAR III, a large randomized clinical trial
comparing intraventricular alteplase with intraventricu-
lar saline for obstructive IVH, found no safety con-
cerns, but no significant benefit was found on the
primary outcome of mRS 0–3 at 180 days between
treatment groups.50 Similar to ICH, extent of IVH
reduction appears to be a critical factor; significant
improvement in functional outcomes occurred only in
the subgroup with >85% IVH clot removal.50
Supportive management and rationale
for bundles of care
In addition to the specific treatments above, the level of
supportive care ICH patients receive in the acute phase
may have a considerable impact on survival and recov-
ery. Difficult decisions may need to be made quickly
regarding appropriate levels of supportive care, ranging
from admission to critical care with full organ support,
to care on a stroke or neurosurgical unit, to withdrawal
of active care and palliation. Such decisions depend on
our ability to reliably predict prognosis, and an overly
pessimistic view may lead to inappropriate limitations
of care—a self-fulfilling prophecy. Evidence suggests
that clinicians are more likely to commence early palli-
ation for ICH compared to ischemic stroke, after
taking demographics, premorbid health, and disease
severity into account.51 Do-not-resuscitate (DNR)
orders are widely used in ICH patients and have been
shown to be independently associated with a worse out-
come,52 with evidence that they may lead to limitations
in care beyond their intended purpose.52 A multicenter
prospective observational study has tested a policy of
avoiding DNR orders in the first five days of care in a
subgroup of patients with severe ICH (GCS 12).53
The observed 30-day case fatality of 20.2% was far
lower than the 50% predicted by the ICH score, and
by 90 days, mRS 0–3 was achieved by 29.9%.53
Multiple grading scales for ICH have been reported
and are moderately predictive of survival and func-
tional recovery,54 but there is some evidence that clin-
ician judgement may be better.55 Given the difficulty in
accurately predicting outcome and the effects of DNR
orders, US guidelines recommend active supportive
care and the postponement of DNR orders until the
second full day of hospitalization.13
There is clear evidence that patients with ICH benefit
at least as much as ischemic strokes from care on a
dedicated stroke unit.56 For more unwell patients who
may require multi-organ support, admission to a crit-
ical care unit should be considered, and observational
studies suggest that care on a dedicated neurological
critical care unit is associated with a lower mortality
than care on a general critical care unit.57
Figure 2. Run chart demonstrating progress in reducing the needle-to-target (NTT) time for intensive BP lowering in ICH
before, during and after implementation of the ABC care bundle at Salford Royal Hospital, UK. The process target of 60 min is
shown by a dashed horizontal line. Each point is the mean NTT for the month when BP lowering was attempted with parenteral
medication. Publication of INTERACT2 did not alter management until a standardized protocol was introduced at bundle
implementation. Further gains were achieved on switching to glyceryl trinitrate as the first-line drug.
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It is well recognized that effective and widespread
implementation of evidence-based care is challenging,
ultimately limiting the benefit of a proven intervention
in day-to-day clinical care.58 This ‘‘translational gap’’
can be especially hard to bridge where interventions
are complex and challenging to implement such as the
time-pressured, hyperacute management of ICH.
Concerted and focused efforts may be required to
improve care processes, with rapid and continuous col-
lection and monitoring of process data, testing of
changes to overcome contextual and disease-specific
barriers, and ultimately working toward pre-defined
process targets. An example of this approach is the
implementation of the ‘‘ABC’’ care bundle at a regional
comprehensive stroke center in the UK.5 The ABC
bundle (standing for Anticoagulant reversal, BP lower-
ing, Care pathway for referral to neurosurgery) served as
a means of focusing the stroke team on delivering
these key interventions rapidly and consistently. Clear-
process targets were designed for each component, and
rapid data collection was established and changes intro-
duced to improve (Figure 2). This led to amarked reduc-
tion in 30-day case fatality (44% reduction after
implementation vs. before) that was not accounted for
by secular trends or case mix.5 Despite not being part of
the ABC bundle, a reduction in DNR orders and
improved access to critical care mediated the observed
improvement in survival. An ICH care bundle focused
on physiological control is currently being tested in the
INTERACT3 cluster-randomized stepped-wedge trial
in China with plans to expand to additional countries
soon. As further evidence emerges for single interven-
tions in ICH, similar approachesmay be needed to accel-
erate and maximize effective implementation, with care
bundles being adapted to incorporate new evidence.
Conclusion
Despite the relatively poor prognosis of ICH, anti-
coagulant reversal, BP lowering, surgery in carefully
selected cases and specialized supportive care may
improve outcomes. These interventions can be challen-
ging to deliver optimally, and a care bundle approach
with proactive review of process data and improve-
ments to care processes may have a significant impact
on outcome. As promising new treatments emerge, they
should be incorporated into care bundles to ensure
rapid and effective implementation.
Box 1. Reversal of anticoagulants
Why?
Anticoagulants are associated with more hematoma expan-
sion and worse outcomes. DOACs are increasingly
(continued)
Box 3. Neurosurgery
Why?
Surgical evacuation of supratentorial ICH may improve clinical
outcomes, provided successful volume reduction can be
achieved: a large randomized controlled trial, MISTIE 3
reported no improvement in functional outcomes although
there was mortality benefit. Patients achieving the surgical
goal of 15 mL residual ICH volume had improved functional
outcome.
Who?
Hematoma evacuation may be more effective in certain sub-
groups, specifically patients in the moderate GCS range
(5–12), with larger hemorrhage volumes (>30 mL). External
ventricular drainage is advised in patients with IVH-associated
(continued)
Box 1. Continued
prescribed and require different reversal strategies.
Which agent?
For VKA-ICH, PCC rapidly restores normal coagulation.
Dabigatran should be reversed with idarucizumab.
Andexanet alfa is licensed for life-threatening bleeding with
rivaroxaban and apixaban. PCC is an alternative treatment for
ICH on anti-Xa agents.
When?
Rapid correction of clotting is associated with a lower risk of
hematoma expansion, so ‘‘time is brain.’’
How?
Ambulance pre-alert for suspected stroke on anticoagulants,
point-of-care testing, immediate access to reversal agents, and
locally agreed protocols can speed reversal.
Box 2. Blood pressure lowering
Why?
BP lowering may reduce hematoma growth and improve clin-
ical outcomes: a large randomised controlled trial,
INTERACT2, reported modest benefits of early (within 6 h
of onset), targeted (systolic BP< 140 mm Hg) BP lowering in
mild-to-moderate severity acute ICH.
How much?
During the first 24 h of treatment, careful (avoiding reductions
60 mm Hg within 1 h), targeted (as low as 120–130 mm Hg),
and sustained (minimizing variability) BP lowering may be opti-
mal.
When?
Ultra-early (<2 h of symptom onset) intensive BP lowering
may have the most potential for reducing hematoma
growth; however, uncertainties remain about the safety of
pre-hospital BP lowering in acute ICH.
Which agent?
There is little evidence on which to base decisions about the
preferred choice of agent. Locally agreed protocols tailored
to clinicians’ familiarity and preferences are reasonable.
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hydrocephalus and decreased level of consciousness.
Evacuation of cerebellar hemorrhage with neurologic deteri-
oration or brainstem compression and/or hydrocephalus is
recommended.
When?
Hematoma evacuation and in particular MIS may be more
effective when performed between 7 and 24 h after onset
although times to evacuation up to 72 h demonstrate efficacy
over conventional therapy.
Which procedure?
Meta-analyses of studies evaluating surgical treatment report
even higher likelihood of good functional outcome and lower
risk of death with MIS (vs. craniotomy) compared to medical
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